Skip to main content
Clinical Trials/NCT01681407
NCT01681407
Terminated
Not Applicable

Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.

HaEmek Medical Center, Israel1 site in 1 country17 target enrollmentNovember 2011
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
HaEmek Medical Center, Israel
Enrollment
17
Locations
1
Primary Endpoint
Depressive symptoms remission or response rates, under usual SSRI treatment.
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device.

The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.

Registry
clinicaltrials.gov
Start Date
November 2011
End Date
February 2014
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amichai Hareven

Dr Amichai Hareven

HaEmek Medical Center, Israel

Eligibility Criteria

Inclusion Criteria

  • Depressed patients,over 18 yo
  • Untreated with SSRI, in the last 3 months

Exclusion Criteria

  • Bipolar patients or another major psychopathology
  • Depressive disorder clearly due to general medical condition, or drug related
  • BMI under 18.5 or above 40
  • Pregnant patients
  • Active suicidality

Outcomes

Primary Outcomes

Depressive symptoms remission or response rates, under usual SSRI treatment.

Time Frame: 10 weeks of follow up

Study Sites (1)

Loading locations...

Similar Trials